Emmessar Biotech & Nutrition Limited (BOM:524768)
23.16
-1.34 (-5.47%)
At close: Sep 25, 2026
BOM:524768 Revenue
Emmessar Biotech & Nutrition had revenue of 5.99M INR in the quarter ending June 30, 2026, a decrease of -4.55%. This brings the company's revenue in the last twelve months to 23.78M, down -12.25% year-over-year. In the fiscal year ending March 31, 2026, Emmessar Biotech & Nutrition had annual revenue of 20.24M, down -5.18%.
Revenue (ttm)
23.78M
Revenue Growth
-12.25%
P/S Ratio
4.87
Revenue / Employee
1.32M
Employees
18
Market Cap
115.71M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 20.24M | -1.11M | -5.18% |
| Mar 31, 2025 | 21.35M | 929.00K | 4.55% |
| Mar 31, 2024 | 20.42M | -4.73M | -18.82% |
| Mar 31, 2023 | 25.15M | 7.42M | 41.83% |
| Mar 31, 2022 | 17.73M | -66.83M | -79.03% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Add-Shop E-Retail | 1.71B |
| Vivanza Biosciences | 1.17B |
| Beryl Drugs | 213.23M |
| Unjha Formulations | 152.79M |
| Zenith Healthcare | 108.46M |
| Norris Medicines | 76.00M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Colinz Laboratories | 58.11M |